Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document KisqaliⓇ FY sales reached USD 2.1bn in metastatic breast cancer (mBC). Maintain USD 4bn peak sales guidance for mBC GROWTH Company overview Financial review Conclusions Appendix References Sales evolution USD m, % cc US Ex-US 357 +76% FY USD 2.1bn +75% 610 278 US MBC NBRx share1 Rolling 3 months, % 208 26% 332 149 Q4 2022 Q4 2023 Nov 2022 46% Nov 2023 Expect continued strong sales momentum in mBC KISQALI® . . Statistically significant OS benefit proven across all 3 Ph3 pivotal trials² Recognized by NCCN guidelines with Category 1 designation for 1L and highest score by ESMO-MCBS3 Median OS of ~5 years across all 3 pivotal trials when combined with letrozole or fulvestrant in 1L mBC Adjuvant indication · Filed in EU, US and China mBC metastatic breast cancer. NBRX - new to brand prescription. NCCN – national comprehensive cancer network. Al - aromatase inhibitor. 1. Of CDK4/6 mBC market, US 3 months ending Nov 2023, IQVIA Breast Cancer Market Sizing report. 2. MONALEESA-2: Hortobagyi et al, NEJM 2022; MONALEESA-7: Lu et al, Clin Cancer Res 2022; MONALEESA-3: Neven et al, ESMO Breast 2022. 3. NCCN Guidelines updated as of 27-Jan-2023. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report. □ NOVARTIS | Reimagining Medicine. Novartis Q4 Results | January 31, 2024 10

View entire presentation